ErVaccine Technologies S.A.

https://www.ervaccinetechnologies.com

LinkedIn: https://www.linkedin.com/company/ervaccine-technologies

ErVaccine Technologies is a preclinical stage biotechnology company, founded in October 2019 by Prof. Stéphane Depil, an onco-haematologist and researcher at the Centre Léon Bérard (CLB) and Centre de Recherche en Cancérologie de Lyon (CRCL), with more than 15 years of experience in pharmaceutical development in oncology. ErVaccine is a spin-off of CLB / CRCL, specialising in the development of next generation therapeutic vaccines and modified T-cell immunotherapies, targeting new families of so-called “unconventional” tumour antigens such as those derived from endogenous retroviruses. ErVaccine Technologies determines tumour epitopes commonly shared by patients through novel bioinformatics algorithms that identify candidate epitopes which are then validated by proteomic approaches and immunological assays. The first targeted indication is triple negative breast cancer, with results obtained in ovarian cancer, sarcoma and acute myeloid leukaemia. The company is embedded in a leading cancer centre @ CRCL/CLB, with a team of high level experts. *

	Start	2019-10-01 established (s-off)
	Industry	cancer vaccine
	Industry 2	drug development
	Person	Donne, Nathalie (ErVaccine 202301 CEO fomerly DBV Technologies 201507)
	Person 2	Depil, Stéphane (Servier 201112 Head Oncology Research & Development)

	Region	Lyon
	Country	France
	Street	28 rue Laennec
	City	69008 Lyon
		Address record changed: 2023-01-11

Basic data	Employees	n. a.

		* Document for »About Section«: ErVaccine Technologies S.A.. (1/5/23). "Press Release: ErVaccine Closes a €4.5 Million Financing Round and Prepares to Start Clinical Trial with Its First Therapeutic Cancer Vaccine in 2023". Lyon.

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for ErVaccine Technologies S.A.

[1] ErVaccine Technologies S.A.. (1/5/23). "Press Release: ErVaccine Closes a €4.5 Million Financing Round and Prepares to Start Clinical Trial with Its First Therapeutic Cancer Vaccine in 2023". Lyon....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]